Research Article
BibTex RIS Cite

Analysis of Carvedilol in Pharmaceutical Preparations by Spectrofluorometric Method

Year 2022, , 188 - 192, 29.06.2022

Bilal Yılmaz

https://doi.org/10.17776/csj.1092393

Abstract

The goal of this research is to develop a spectrofluorometric method for analyzing carvedilol in pharmaceutical preparations and apply this method to the formulations. The method’s calibration curve was plotted between 25 and 500 ng/mL. The mean calibration equation from six replicate experiments is y=1.8736x+7.7291. The correlation coefficient value was higher than 0.997 for the mean calibration curve. The trueness results were better than 2.09% and the precision results were less than 2.73% for carvedilol. The detection and quantitation limits were determined as 2.196 and 6.654 ng/mL, respectively. In addition, the method was used to study carvedilol in pharmaceutical preparations. The method had recovery values >98.4% for all samples in pharmaceutical preparations. The detection wavelength was optimized to maximize the sensitivity of the method. This method has good sensitivity with satisfactory results. Therefore, the method can be used in carvedilol analysis.

Keywords

Cocklebur Biodiesel Fatty acids Linoleic acid.

Thanks

The author would like to thank Semih Yilmaz for expert advice on the use of English.

References

  • [1] Karle C.A., Kreye V.A.W., Thomas D., Rockl K., Kathofer S., Zhang W., Kiehnet J., Antiarrhythmic Drug Carvedilol Inhibits HERG Potassium Channels, Cardiovascular Res., 49 (2001) 361-370.
  • [2] Chen J.J., Shih N.L., Carvedilol: An Anti-Inflammatory and Anti-Atherogenic β-blocker, Acta Cardiol. Sin., 19 (2003) 93-94.
  • [3] Franciosa J.A., Massie B.M., Lukas M.A., Nelson J.J., Lottes S., Abraham W.T., Fowler M., Gilbert E.M., Greenberg B., β-blocker Therapy for Heart Failure Outside the Clinical Trial Setting: Findings of a Community-based Registry, American Heart J., 148 (2004) 718-726.
  • [4] Stoschitzky K., Koshucharova G., Lercher P., Maier R., Sakotnik A., Klein W., Liebmann P.M., Lindner W., Stereoselective Effects of (R)- and (S)-carvedilol in Humans, Chirality., 13 (2001) 342-346.
  • [5] Nath B., Nath L.K., Kumar P.Y., Preparation and In vitro Evaluation of Buccoadhesive Tablets of Carvedilol Using Dried Mucilage Powder of Aegle marmelose, Research J. Pharm. Tech., 2 (2009) 762-767.
  • [6] Desai D.C., Karkhanis V.V., Simple spectrophotometric estimation of carvedilol phosphate in bulk and tablet dosage forms, Int. Res. J. Pharm., 3 (2012) 114-116.
  • [7] Patel S.A., Patel N.J., Validated Spectrophotometric Methods for the Determination of Carvedilol in Tablets, Int. Res. J. Pharm., 2 (2011) 171-175.
  • [8] Theivarasu C., Santanu G., Indumarthi T., UV Spectrophotometric Determination of Carvedilol in Pharmaceutical Formulations, Asian J. Pharm. Clin. Res., 3 (2010) 64-68.
  • [9] Shinkar D.M., Dhake A.S., Setty C.M., Development of UV Spectrophotometric Method for estimation of Carvedilol in Bulk and Pharmaceutical Formulations, Asian J.Res. Chem., 6 (2013) 956-959.
  • [10] Vinod T., Sachin G., Omprakash B., Development, Validation and Stability Study of UV Spectrophotometric Method for Determination of Carvedilol Phosphate in Bulk and Pharmaceutical Dosage Forms, Int. J. ChemTech Res., 10 (2017) 252-259.
  • [11] Divya N.S., Narayana B., Simple Methods for the Spectrophotometric Determination of Carvedilol, Int. Scholarly Res. Network, 6 (2012) 373215.
  • [12] Audumbar M., Vikas K., Rohan D., Sachin G., Ritesh B., Simultaneous UV Spectrophotometric Methods for Estimation of Carvedilol and Hydrochlorothiazide in Bulk and Tablet Dosage Form, Asian J. Pharm. Tech., 6 (2016) 15-20.
  • [13] Rajan V.R., Prathamesh P.T., UV Spectrophotometric Estimation of Carvedilol Hydrochloride by Second Order Derivative Methods in Bulk and Pharmaceutical Dosage Form, Res. J. Pharm. Tech., 7 (2014) 1459-1462.
  • [14] Sayed M.D., Mahmoud A.O., Mohamed A.K.A.L., Ahmed I.H., Development and Validation of a New Spectrofluorometric Method for the Determination of Some Beta-blockers through Fluorescence Quenching of Eosin Y, Open Chem. J., 14 (2016) 258-266.
  • [15] Sovan L.P., Utpal J.G., Mohanta P., Manna P.K., Method Development and Validation of Reverse Phase High Performance Liquid Chromatography Method to Determine Carvedilol in Pharmaceutical Formulations, Der Pharm. Sin., 4 (2013) 22-27.
  • [16] Sivakamasundari G., Kannappan N., Development and Validation of RP-UPLC Method for the Simultaneous estimation of Carvedilol and Hydrochlorothiazide in Pharmaceutical Dosage Form, Int. Res. J. Pharm., 9 (2018) 23-26.
  • [17] Rao U.V.M., Haritha G., Krishnaiah T., Saikiran T.G., Reddy T.A., Nikhil U.V.S., Veerabomma H.S., Veeram S.D.R., Method Development and Forced Degradation Studies of Carvedilol by RP-HPLC, Int. J. Pharm. Anal. Res., 6 (2017) 457-468.
  • [18] Patel H., Jivani N., Development of Validated RP-HPLC Method for Simultaneous Estimation of Carvedilol and Ivabradine, World J. Pharm.Pharmaceut. Sci., 4 (2015) 630-639.
  • [19] El-Adl S.M., Abdel-Aziz L.M., Mohamed M.A.M., HPLC Determination of Carvedilol and Atorvastatin Calcium in Their Bulk and Dosage Form, Asian J. Pharm. Anal. Med. Chem., 4 (2016) 112-123.
  • [20] Suganthi A., Ravi T.K., Development of RP-HPLC Method for the Estimation of Nebivolol and Carvedilol with selected NSAIDS and its Application to Drug Displacement Interaction Studies, Malaysian J.Pharmaceut. Sci., 12 (2014) 47-65.
  • [21] Mahaveer S., Kashkhedikar S.G., Soni L., Abhinav G., Tripti G., Amrish P., Development of RP-HPLC Method for Estimation of Carvedilol in Tablet Formulations, Res. J. Pharm. Tech., 1 (2008) 18-21.
  • [22] Clohs L., McErlane K.M., Development of a Capillary Electrophoresis Assay for the Determination of Carvedilol Enantiomers in Serum using Cyclodextrins, J. Pharm. Biomed. Anal., 24 (2001) 545-554.
  • [23] Samin H., Somaieh S., Abolghasem J., A dispersive liquid-liquid microextraction and chiral separation of Carvedilol in Human plasma using Capillary Electrophoresis, Bioanalysis., 7 (2015) 1107-1117.
  • [24] ICH Topic Q 2 (R1) Validation of Analytical Procedures: Text and Methodology, Note for Guidance on Validation of Analytical Procedures: Text And Methodology (CPMP/ICH/381/95).
  • [25] British Pharmacopoeia, The Stationery Office, London, (2009) 374.
  • [26] Dogan B., Ozkan S.A., Electrochemical Behavior of Carvedilol and its Adsorptive Stripping Determination in Dosage Forms and Biological Fluids, Electroanal., 17 (2005) 2074-2083.
  • [27] Streim K., Sponer G., Muller B., Bartsch W., Pharmacological Profile of Caevedilol: A Compound with β-Blocking and Vasodilating Properties, J. Cardiovas. Pharm., 10 (1987) 33-41.
  • [28] Bartsch W., Sponer G., Muller B., Kling L., Bohm E., Martin U., Borbe H.O., Pharmacological Characteristics of the Stereoisomers of Carvedilol, European J. Clin. Pharm., 38 (1990) 104-107.

Year 2022, , 188 - 192, 29.06.2022

Bilal Yılmaz

https://doi.org/10.17776/csj.1092393

Abstract

References

  • [1] Karle C.A., Kreye V.A.W., Thomas D., Rockl K., Kathofer S., Zhang W., Kiehnet J., Antiarrhythmic Drug Carvedilol Inhibits HERG Potassium Channels, Cardiovascular Res., 49 (2001) 361-370.
  • [2] Chen J.J., Shih N.L., Carvedilol: An Anti-Inflammatory and Anti-Atherogenic β-blocker, Acta Cardiol. Sin., 19 (2003) 93-94.
  • [3] Franciosa J.A., Massie B.M., Lukas M.A., Nelson J.J., Lottes S., Abraham W.T., Fowler M., Gilbert E.M., Greenberg B., β-blocker Therapy for Heart Failure Outside the Clinical Trial Setting: Findings of a Community-based Registry, American Heart J., 148 (2004) 718-726.
  • [4] Stoschitzky K., Koshucharova G., Lercher P., Maier R., Sakotnik A., Klein W., Liebmann P.M., Lindner W., Stereoselective Effects of (R)- and (S)-carvedilol in Humans, Chirality., 13 (2001) 342-346.
  • [5] Nath B., Nath L.K., Kumar P.Y., Preparation and In vitro Evaluation of Buccoadhesive Tablets of Carvedilol Using Dried Mucilage Powder of Aegle marmelose, Research J. Pharm. Tech., 2 (2009) 762-767.
  • [6] Desai D.C., Karkhanis V.V., Simple spectrophotometric estimation of carvedilol phosphate in bulk and tablet dosage forms, Int. Res. J. Pharm., 3 (2012) 114-116.
  • [7] Patel S.A., Patel N.J., Validated Spectrophotometric Methods for the Determination of Carvedilol in Tablets, Int. Res. J. Pharm., 2 (2011) 171-175.
  • [8] Theivarasu C., Santanu G., Indumarthi T., UV Spectrophotometric Determination of Carvedilol in Pharmaceutical Formulations, Asian J. Pharm. Clin. Res., 3 (2010) 64-68.
  • [9] Shinkar D.M., Dhake A.S., Setty C.M., Development of UV Spectrophotometric Method for estimation of Carvedilol in Bulk and Pharmaceutical Formulations, Asian J.Res. Chem., 6 (2013) 956-959.
  • [10] Vinod T., Sachin G., Omprakash B., Development, Validation and Stability Study of UV Spectrophotometric Method for Determination of Carvedilol Phosphate in Bulk and Pharmaceutical Dosage Forms, Int. J. ChemTech Res., 10 (2017) 252-259.
  • [11] Divya N.S., Narayana B., Simple Methods for the Spectrophotometric Determination of Carvedilol, Int. Scholarly Res. Network, 6 (2012) 373215.
  • [12] Audumbar M., Vikas K., Rohan D., Sachin G., Ritesh B., Simultaneous UV Spectrophotometric Methods for Estimation of Carvedilol and Hydrochlorothiazide in Bulk and Tablet Dosage Form, Asian J. Pharm. Tech., 6 (2016) 15-20.
  • [13] Rajan V.R., Prathamesh P.T., UV Spectrophotometric Estimation of Carvedilol Hydrochloride by Second Order Derivative Methods in Bulk and Pharmaceutical Dosage Form, Res. J. Pharm. Tech., 7 (2014) 1459-1462.
  • [14] Sayed M.D., Mahmoud A.O., Mohamed A.K.A.L., Ahmed I.H., Development and Validation of a New Spectrofluorometric Method for the Determination of Some Beta-blockers through Fluorescence Quenching of Eosin Y, Open Chem. J., 14 (2016) 258-266.
  • [15] Sovan L.P., Utpal J.G., Mohanta P., Manna P.K., Method Development and Validation of Reverse Phase High Performance Liquid Chromatography Method to Determine Carvedilol in Pharmaceutical Formulations, Der Pharm. Sin., 4 (2013) 22-27.
  • [16] Sivakamasundari G., Kannappan N., Development and Validation of RP-UPLC Method for the Simultaneous estimation of Carvedilol and Hydrochlorothiazide in Pharmaceutical Dosage Form, Int. Res. J. Pharm., 9 (2018) 23-26.
  • [17] Rao U.V.M., Haritha G., Krishnaiah T., Saikiran T.G., Reddy T.A., Nikhil U.V.S., Veerabomma H.S., Veeram S.D.R., Method Development and Forced Degradation Studies of Carvedilol by RP-HPLC, Int. J. Pharm. Anal. Res., 6 (2017) 457-468.
  • [18] Patel H., Jivani N., Development of Validated RP-HPLC Method for Simultaneous Estimation of Carvedilol and Ivabradine, World J. Pharm.Pharmaceut. Sci., 4 (2015) 630-639.
  • [19] El-Adl S.M., Abdel-Aziz L.M., Mohamed M.A.M., HPLC Determination of Carvedilol and Atorvastatin Calcium in Their Bulk and Dosage Form, Asian J. Pharm. Anal. Med. Chem., 4 (2016) 112-123.
  • [20] Suganthi A., Ravi T.K., Development of RP-HPLC Method for the Estimation of Nebivolol and Carvedilol with selected NSAIDS and its Application to Drug Displacement Interaction Studies, Malaysian J.Pharmaceut. Sci., 12 (2014) 47-65.
  • [21] Mahaveer S., Kashkhedikar S.G., Soni L., Abhinav G., Tripti G., Amrish P., Development of RP-HPLC Method for Estimation of Carvedilol in Tablet Formulations, Res. J. Pharm. Tech., 1 (2008) 18-21.
  • [22] Clohs L., McErlane K.M., Development of a Capillary Electrophoresis Assay for the Determination of Carvedilol Enantiomers in Serum using Cyclodextrins, J. Pharm. Biomed. Anal., 24 (2001) 545-554.
  • [23] Samin H., Somaieh S., Abolghasem J., A dispersive liquid-liquid microextraction and chiral separation of Carvedilol in Human plasma using Capillary Electrophoresis, Bioanalysis., 7 (2015) 1107-1117.
  • [24] ICH Topic Q 2 (R1) Validation of Analytical Procedures: Text and Methodology, Note for Guidance on Validation of Analytical Procedures: Text And Methodology (CPMP/ICH/381/95).
  • [25] British Pharmacopoeia, The Stationery Office, London, (2009) 374.
  • [26] Dogan B., Ozkan S.A., Electrochemical Behavior of Carvedilol and its Adsorptive Stripping Determination in Dosage Forms and Biological Fluids, Electroanal., 17 (2005) 2074-2083.
  • [27] Streim K., Sponer G., Muller B., Bartsch W., Pharmacological Profile of Caevedilol: A Compound with β-Blocking and Vasodilating Properties, J. Cardiovas. Pharm., 10 (1987) 33-41.
  • [28] Bartsch W., Sponer G., Muller B., Kling L., Bohm E., Martin U., Borbe H.O., Pharmacological Characteristics of the Stereoisomers of Carvedilol, European J. Clin. Pharm., 38 (1990) 104-107.
There are 28 citations in total.

Details

Primary Language English
Subjects Nonlinear Optics and Spectroscopy
Journal Section Natural Sciences
Authors

Bilal Yılmaz 0000-0002-8574-7570

Publication Date June 29, 2022
Submission Date March 24, 2022
Acceptance Date June 2, 2022
Published in Issue Year 2022

Cite

APA Yılmaz, B. (2022). Analysis of Carvedilol in Pharmaceutical Preparations by Spectrofluorometric Method. Cumhuriyet Science Journal, 43(2), 188-192. https://doi.org/10.17776/csj.1092393